The funding would be utilised to expand company's operations, RAL said in a statement.
"Our next target is to generate a revenue of Rs 500 crore by 2020 and strengthening our position in the ever-growing niche segment of steriles," RAL MD Ashish Pruthi said.
Incorporated in 1986, the company commenced commercial production 1991. It manufactures active pharmaceutical ingredients (API).